BioSpace News Archive

ImmunoGen Inc, today announced initial safety and preliminary anti-tumor activity from the FORWARD II expansion cohort assessing mirvetuximab soravtansine

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA,

Exelixis, Inc. (NASDAQ:EXEL) today announced results from two analyses evaluating the effect of PD-L1 expression or prior treatment with immune checkpoint inhibitors on the efficacy of cabozantinib in patients with advanced renal cell carcinoma (RCC).

New Clinical Findings Involving STING Agonist as Monotherapy and in Combination with an Anti-PD-1 Therapy

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of CV Sciences, Inc. (OTC: CVSI) from June 19, 2017 through August 20, 2018

Results Presented at the ESMO 2018 Congress (European Society for Medical Oncology) and Simultaneously Published in The New England Journal of Medicine

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents.

Varian (NYSE: VAR) today announced its new single-room proton therapy system, ProBeam® 360°.

To expand the encouraging preclinical and translational research already conducted by Varian (NYSE: VAR) and two of its clinical partners, Maryland Proton Treatment Center and Cincinnati Children’s/UC Health Proton Therapy Center,

Bristol-Myers Squibb Company (NYSE: BMY) today announced follow-up data evaluating Opdivo (nivolumab) monotherapy and Opdivo in combination with Yervoy (ipilimumab) in patients with platinum-pretreated metastatic urothelial carcinoma (mUC)